Active Not Recruiting PHASE3 INTERVENTIONAL 5-arm NCT03972488

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Sponsor: Advanced Accelerator Applications

Conditions Gastro-enteropancreatic Neuroendocrine Tumor

Interventions 2.5% Lys-Arg sterile amino acid solution 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot) High dose 60 mg octreotide long-acting repeatable Lutathera

Updated 30 times since 2019 Last updated: Jan 4, 2026 Started: Jan 8, 2020 Primary completion: Jul 20, 2023 Completion: Oct 29, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03972488, this PHASE3 trial focuses on Gastro-enteropancreatic Neuroendocrine Tumor and remains ongoing. Sponsored by Advanced Accelerator Applications, it has been updated 30 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

30 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Nov 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 25 earlier versions

Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE3
Nov 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE3
Aug 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE3
Jun 2023 — Aug 2023 [monthly]

Active Not Recruiting PHASE3
Nov 2022 — Jun 2023 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Apr 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE3
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE3
Nov 2021 — Jan 2022 [monthly]

Recruiting PHASE3
Sep 2021 — Nov 2021 [monthly]

Recruiting PHASE3
May 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Jan 2021 — May 2021 [monthly]

Recruiting PHASE3
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE3
May 2020 — Jul 2020 [monthly]

Recruiting PHASE3
Apr 2020 — May 2020 [monthly]

Recruiting PHASE3
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Feb 2020 — Mar 2020 [monthly]

Not Yet Recruiting PHASE3
Oct 2019 — Feb 2020 [monthly]

Not Yet Recruiting PHASE3
Jul 2019 — Oct 2019 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Advanced Accelerator Applications

Data source: Advanced Accelerator Applications

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bologna, Italy , Bristol, United Kingdom , Clichy, France , Erlangen, Germany , Essen, Germany , Genova, Italy , Houston, United States , Iowa City, United States , Lexington, United States and 24 more locations